BCL2 is an antiapoptotic factor, and its deregulation in NHL is associated with the constitutive activation of NF-κB, which in turn influences the therapeutic response and prognosis of these patients (75, 76). This evidence concerns the gene BCL2 and non-Hodgkin lymphoma.